Ovarian cancer is the leading cause of death from gynecologic cancers in the United States. Failure may be due to variable expression and/or complex interactions of growth factor receptors in individual tumors. As ErbB3-MET cooperativity is implicated in solid tumor resistance to EGFR/ErbB2 inhibitors, we evaluated expression of MET and all 4 ErbB family members in ovarian cancers. Tissue arrays were prepared from archival formalin-fixed paraffin-embedded tumor samples, including 202 ovarian carcinomas (Stage I-IV) and controls. Of 202 patient samples, only 25% were positive for EGFR and 35% for ErbB2 expression. ErbB3, ErbB4, and MET showed marked expression in 76%, 98%, and 96% of cases. Consistent with high incidence, there was no significant correlation for expression of ErbB3, ErbB4, or MET with outcome. On the basis of their high expression in the majority of cases, inhibitors targeting ErbB3, ErbB4, and/or MET may be broadly applicable as therapeutic agents in this disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153698 | PMC |
| http://dx.doi.org/10.1097/PGP.0000000000000081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ERBB2/ERBB3-mutated S100/SOX10-positive uterine sarcoma: something new.
Virchows Arch
December 2024
Department of Pathology, University of California San Diego Health, 9300 Campus Point Drive, Suite 1-200, La Jolla, MC 7723, San Diego, CA, 92037, USA.
A distinctive subset of uterine mesenchymal tumors display recurrent genetic fusions involving receptor tyrosine kinases, including NTRK, PDGFB, FGFR1, and RET, presumably leading to aberrant pathway activation. A pair of recent studies have highlighted the existence of a genetic fusion-negative uterine sarcoma that is characterized by activating mutations in ERBB2/ERBB3, CDKN2A deletion, inactivating ATRX mutation, and a S100 + /SOX10 + immunohistochemical profile. This report describes another case of this emerging entity that was diagnosed in a 57-year-old woman.
View Article and Find Full Text PDFPre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
Oncoimmunology
December 2024
Pacific Neuroscience Institute, Neuro-Oncology, Santa Monica, CA, USA.
The limited success of immune checkpoint inhibitors (ICIs) in the adjuvant setting for glioblastoma highlights the need to explore administering ICIs prior to immunosuppressive radiation. To address the feasibility and safety of this approach, we conducted a phase I study in patients with newly diagnosed Grade 3 and Grade 4 gliomas. Patients received nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks until disease progression or unacceptable toxicity.
View Article and Find Full Text PDFEstablishing a new human lung squamous cell carcinoma cell line, OMUL-1, expressing insulin-like growth factor 1 receptor and programmed cell death ligand 1.
Thorac Cancer
January 2025
Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
The Main Problem: Squamous cell carcinoma is the second most prevalent type of non-small cell lung cancer. Analyzing the molecular mechanisms underlying lung carcinoma requires useful tools, such as squamous lung cancer cell lines.
Methods: A novel new lung squamous cell carcinoma cell line, OMUL-1, was developed from the primary lung cancer of a 74-year-old man.
CDX2-Suppressed Colorectal Cancers Possess Potentially Targetable Alterations in Receptor Tyrosine Kinases and Other Colorectal-Cancer-Associated Pathways.
Diseases
October 2024
Algoma District Cancer Program, Sault Area Hospital, Sault Ste. Marie, ON P6B 0A8, Canada.
Background: Colorectal cancer, a prevalent gastrointestinal carcinoma, has a high risk for recurrence when locally advanced and remains lethal when in an advanced stage. Prognostic biomarkers may help in better delineating the aggressiveness of this disease in individual patients and help to tailor appropriate therapies. CDX2, a transcription factor of gastrointestinal differentiation, has been proposed as a biomarker for good outcomes and could also be a marker of specific sub-types amenable to targeted therapies.
View Article and Find Full Text PDFTargeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies.
Front Pharmacol
August 2024
College of Medicine, QU Health, Qatar University, Doha, Qatar.
Article Synopsis
- The epidermal growth factor receptor (EGFR, also known as ErbB1/HER1) is a key receptor involved in kidney development and repair, but its prolonged activation can lead to various kidney diseases like diabetic nephropathy and chronic kidney disease.
- Recent research highlights the effects of EGFR activation on kidney health and suggests a possible protective role of the angiotensin-(1-7) peptide, which may inhibit EGFR’s harmful effects.
- The review proposes that EGFR inhibitors already used for cancer treatment, like Gefitinib and Erlotinib, could be repurposed to treat kidney-related issues due to their proven safety and effectiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!